<SEC-DOCUMENT>0001818382-22-000179.txt : 20221110
<SEC-HEADER>0001818382-22-000179.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110070442
ACCESSION NUMBER:		0001818382-22-000179
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		221374874

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20221110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a2ee5820-b42e-4233-97a4-541eaa39e606,g:448f800f-0fd0-43fb-85cb-7b31a34c1e9b,d:a8057c349b1b41a09dc39b88e58fe7bb--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20221110</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl80L2ZyYWc6YmUxMmNlMWE1OTQ5NGM4OGI3ZTI5NjUwZmQwMDMwMjYvdGFibGU6MTg3YTJhMWJkNDZlNGY5YWEwMzBhNzQ2MTE1ZmViNWMvdGFibGVyYW5nZToxODdhMmExYmQ0NmU0ZjlhYTAzMGE3NDYxMTVmZWI1Y18xLTEtMS0xLTU3MTMz_11fd74d6-8bf8-435c-9b51-3f33c89fb2fc">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl80L2ZyYWc6YmUxMmNlMWE1OTQ5NGM4OGI3ZTI5NjUwZmQwMDMwMjYvdGFibGU6MTg3YTJhMWJkNDZlNGY5YWEwMzBhNzQ2MTE1ZmViNWMvdGFibGVyYW5nZToxODdhMmExYmQ0NmU0ZjlhYTAzMGE3NDYxMTVmZWI1Y18yLTEtMS0xLTU3MTMz_c55f599c-415c-4ea6-bbfc-447c503aaf6e">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20221110.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia299eba8191d4c46a191713c02621e07_D20221110-20221110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-10</xbrli:startDate><xbrli:endDate>2022-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia8057c349b1b41a09dc39b88e58fe7bb_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIw_5a0b0620-2494-49da-a2b6-d491135a1970">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIx_d59ca478-55dd-42af-a6c7-65a4b3753cd2">November 10, 2022</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIy_901b3c41-4e53-4f5a-9c20-e1741e6890e4"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIz_86603769-ed10-4824-b735-973509fb2049">Humacyte, Inc.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6NmQ1ZDIxNjZjNWU4NDZhM2JlM2I1YmYwODFhY2EyOTgvdGFibGVyYW5nZTo2ZDVkMjE2NmM1ZTg0NmEzYmUzYjViZjA4MWFjYTI5OF8wLTAtMS0xLTU3MTMz_d2f1ac13-e101-46be-ad86-5f273b224145">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6NmQ1ZDIxNjZjNWU4NDZhM2JlM2I1YmYwODFhY2EyOTgvdGFibGVyYW5nZTo2ZDVkMjE2NmM1ZTg0NmEzYmUzYjViZjA4MWFjYTI5OF8wLTEtMS0xLTU3MTMz_6f244117-23ba-41e4-a780-be38eda2b3ea">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6NmQ1ZDIxNjZjNWU4NDZhM2JlM2I1YmYwODFhY2EyOTgvdGFibGVyYW5nZTo2ZDVkMjE2NmM1ZTg0NmEzYmUzYjViZjA4MWFjYTI5OF8wLTItMS0xLTU3MTMz_5359243e-c489-4515-9571-813ede86f47c">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18wLTAtMS0xLTU3MTMz_c8b6103d-f234-4a12-87c5-03699a051139">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18xLTAtMS0xLTU3MTMz_9fa4c9af-b7e1-43a1-a3ac-6729b1204b1e">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18xLTEtMS0xLTU3MTMz_671711f5-6183-4328-a523-04287474643f">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18xLTItMS0xLTU3MTMz_92e7336b-d96d-436a-9f2d-196db9eb91c4">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8zMjU_c4c47d68-b877-43b9-b71f-abf4a6e173b8">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjI0_4954b877-3626-43ec-b2b8-43b5ae2a86a0">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8wLTAtMS0xLTU3MTMz_d23be0fb-8bc5-458a-a693-69796eb92568">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8xLTAtMS0xLTU3MTMz_92ed797e-1e64-4b17-8c74-b9f2701e69fe">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8yLTAtMS0xLTU3MTMz_819fd7e2-980a-4b0f-8ed5-d403325f413a">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8zLTAtMS0xLTU3MTMz_5acf124e-feff-4419-97d2-e2455f53d554">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8xLTAtMS0xLTU3MTMz_4240e115-f5b0-453a-af89-86980ee29ec4">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8xLTItMS0xLTU3MTMz_8f000705-e8b1-46d5-81f9-9db05297a6a4">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8xLTQtMS0xLTU3MTMz_ae8aff5e-0913-475b-b720-29dcc694ac85">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia299eba8191d4c46a191713c02621e07_D20221110-20221110" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8yLTAtMS0xLTU3MTMz_37f03e42-0486-423a-9019-011f8023abe2">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia299eba8191d4c46a191713c02621e07_D20221110-20221110" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8yLTItMS0xLTU3MTMz_471791b0-7852-46f5-bced-a7f0f7a5aa96">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia299eba8191d4c46a191713c02621e07_D20221110-20221110" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8yLTQtMS0xLTU3MTMz_82c48db2-d72f-4c8e-bee3-0b931229a7c1">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjE4_1da69b19-f2a8-4ea7-99e4-0468f0a59c81">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjE5_fb902e8c-4e89-4f9b-a28d-315e5875cca2">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ia8057c349b1b41a09dc39b88e58fe7bb_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September&#160;30, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="ia8057c349b1b41a09dc39b88e58fe7bb_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20221110xexx991.htm">Press release, dated November 10, 2022.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia8057c349b1b41a09dc39b88e58fe7bb_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20221110xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id66ef82128f44905b9d61a27a37616fa_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:center"><img alt="image.jpg" src="image.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:210px"></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Quarter 2022 Financial Results and Business Update</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">--</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Progress Continues in Clinical Development of Human Acellular Vessel&#8482; (HAV&#8482;) for Vascular Trauma&#59; BLA Filing Anticipated mid 2023 &#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">--</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Experience with HAV in Ukrainian War Vascular Trauma Mirrors Clinical Experiences in Civilians in the U.S., <br>High Patency and Low Rates of Amputation and Infection Observed</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">--</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-Clinical Studies of Small Diameter HAV in Coronary Bypass Continue to be Promising </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">--</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Strengthened Board of Directors with Appointment of Lt. General C. Bruce Green, M.D., USAF-ret and Senior Management Team with Appointment of Yang (Cindy) Cao, Ph.D. as Chief Regulatory Officer </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">--</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conference Call and Live Webcast at 8&#58;00 a.m. ET Today </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font></div><div style="margin-top:16pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DURHAM, N.C., November 10, 2022 -- </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tissues, advanced tissue constructs and organ systems at commercial scale, today announced financial results for the third quar</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ter ended September&#160;30, 2022, and highlighted recent corporate accomplishments.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;The third quarter of 2023 proved to be highly productive for Humacyte, with continued progress across our clinical and preclinical programs and multiple data presentations at key medical meetings,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;We expect to file our Biologics License Application (BLA) for an indication in vascular trauma in mid 2023. We are pleased with the trial&#8217;s progress and the positive results obtained to date. In addition, we are proud to be partnering with the Diabetes Research Institute to support our Biovascular Pancreas product development program in severe type 1 diabetes. The opportunity to work with the outstanding scientists and physicians at DRI is an exciting addition to our BVP program that we anticipate will accelerate our product development. Finally, we welcome to the Humacyte leadership team Dr. Lt. General Bruce Green and Dr. Cindy Cao, whose extensive expertise will be invaluable as our HAVs continue to progress toward approval.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2022 and Recent Corporate Highlights</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for an indication in vascular trauma in mid 2023. As of October 31, 2022, 56 patients had received the HAV in the V005 Phase 2&#47;3 clinical trial in vascular trauma. V005 is an open-label study and to date we have observed high rates of patency, low rates of amputation and only one case of HAV infection in the V005 trial. In addition, the preliminary results of the first nine patients treated under the humanitarian program in Ukraine have been shared with the FDA, and the Company expects to supplement the V005 data with these complementary results. The Company also plans to open a Clinical Trial Application in Ukraine and plans to enable enrollment of additional patients in the V005 clinical trial.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Humacyte initiated a research partnership with the Diabetes Research Institute (DRI) in Miami, Florida, a global leader in pre-clinical studies of novel diabetic therapies, to facilitate development of the Biovascular Pancreas (BVP), a product candidate designed to treat patients with severe type 1 diabetes.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment is nearing completion in our Phase 3 trial of the HAV for arteriovenous (AV) access in hemodialysis patients. The V007 trial is designed to assess the usability of the HAV for hemodialysis, in comparison to autogenous fistulas, in up to 240 patients with end stage renal disease. With 227 patients enrolled as of October 26, 2022, we anticipate that enrollment will be completed soon. Top-line results are anticipated one year after enrollment completion, based upon the one-year follow-up period built into the study. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Publications and Presentations</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2022, the U.S. Army published an update affirming their support of the development of the HAV in trauma. In an article entitled &#8220;How an Army-funded &#8216;bioengineered blood vessel&#8217; is saving lives in Ukraine,&#8221; the Army reported that officials with the Defense Department encouraged Humacyte to collaborate with the Medical Technology Enterprise Consortium (MTEC), which helps identify new medical solutions for warfighters. MTEC has already provided more than $6.8 million in funding to Humacyte to develop the HAV.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ukrainian surgeons presented patient outcomes from the use of the HAV to treat wartime vascular trauma at the European Society for Vascular Surgery Annual Meeting in Rome in September 2022. The surgeons described long-standing limitations in vascular tissue repair and replacement as well as the injuries that they have observed during the Russian-Ukrainian conflict. Surgeons have utilized the HAV to treat patients with a multitude of wartime injuries including blast trauma, shrapnel injuries, and gunshot wounds. The surgeons observed that access to the HAV, a biologic conduit, has improved their ability to perform vascular reconstructions by eliminating the need to harvest a venous conduit. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2022, Todd E. Rasmussen M.D., FACS, (Col, ret. USAF MC) and Charles J. Fox M.D. provided a clinical update on the HAV for the treatment of vascular trauma at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium. Speaking to an audience of NATO and other international surgeons, Drs. Rasmussen and Fox observed that injured service members and those with certain complex injuries in the civilian sector could benefit from the use of a readily available and infection resistant vascular conduit, such as the HAV, that would facilitate quick implantation, particularly in the setting of contaminated wounds.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2022, preclinical data on use of the small-diameter HAV in coronary artery bypass grafting (CABG) was presented at American Heart Association Basic Cardiovascular Sciences Scientific Sessions. Coronary bypass in a non-human primate model, with follow-up of 6 months, showed that the HAV maintained structural integrity and functioned well to conduct blood flow to the heart. In addition, the HAV had robust cell repopulation with vascular cells over time, becoming a living vascular tissue supplying the heart muscle. Updated data from this study, consistent with these findings, were also reported at the American Heart Association (AHA) Scientific Sessions annual meeting in Chicago on November 6, 2022.</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2022, pharma industry veteran Yang (Cindy) Cao, Ph.D. joined as the Company&#8217;s Chief Regulatory Officer. Dr. Cao brings over twenty years of drug discovery and development experience in pharmaceutical and biotech companies, including Bristol-Myer Squibb, Novartis, Novo Nordisk and Sanofi. Dr. Cao has extensive expertise in global and US regulatory strategy and policy on biologics, small molecules, and devices, and has provided guidance to development teams in various therapeutic areas. Dr. Cao holds a B.S. in genetics from Fudan University in Shanghai China, and a Ph.D. in biomedical sciences from University of New Mexico.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Also in September 2022, Humacyte strengthened its Board of Directors with the appointment of Lt. General C. Bruce Green, M.D., USAF-ret., former Surgeon General of the U.S. Air Force. As command surgeon for three major commands, he planned joint medical response for operations Desert Thunder and Desert Fox, and oversaw aeromedical evacuation for operations Enduring Freedom and Iraqi Freedom. General Green earned a B.S. in chemistry at the University of Wisconsin-Parkside and an M.D. at the Medical College of Wisconsin.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is continuing to strengthen its relationship with its global partner and shareholder Fresenius Medical Care, the global market leader in kidney care services, products and value-based care. Humacyte is partnering with Frenova, a clinical research group owned by Fresenius Medical Care, to evaluate the complications and costs of hemodialysis access care for vulnerable patients in both the US and Europe. Data from more than 600,000 anonymized patients, concerning demographics, access complications and failures, infections, hospitalization and mortality is being analyzed to provide targeted information on those patients who may most benefit from the HAV.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2022 Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash, cash equivalents and short-term investments of $171.7 million as of September&#160;30, 2022, compared to $225.5 million as of December&#160;31, 2021. The $53.8 million net use of cash, cash equivalents and short-term investments for the first nine months of 2022 resulted from spending related to net operating activities for the period, including clinical and earlier-stage research and development programs, and preparation for the Company&#8217;s anticipated commercial launch. The Company believes that its cash, cash equivalents and short-term investments are adequate to fund operations through 2024, past the Company&#8217;s current expected timeline for potential approval of the HAV in vascular trauma.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue was $31 thousand for the third quarter of 2022, compared to $0.2 million for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of 2021, and was $1.6 million for the nine months ended September&#160;30, 2022, compared to $1.1 million for the nine months ended September&#160;30, 2021. Revenue in all periods related to grants supporting the development of the HAV.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $17.3 million for the third quarter of 2022, compared to $15.4 million for the third quarter of 2021, and were $48.3 million for the nine months ended September&#160;30, 2022, compared to $45.1 million for the nine months ended September&#160;30, 2021. The current-period increases resulted primarily from increased personnel expenses to support expanded research and development initiatives and the support of clinical trials.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $6.2 million for the third quarter of 2022, compared to $5.4 million for the third quarter of 2021, and were $17.1 million for the nine months ended September&#160;30, 2022, compared to $15.6 million for the nine months ended September&#160;30, 2021. The current-period increases resulted primarily from the transition to being a public company and preparation for the anticipated U.S. commercial launch of the HAV, including increased personnel costs, professional fees and insurance costs.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net expense was $1.8 million for the third quarter of 2022, compared to $11.0 million for the third quarter of 2021, and other net income was $55.5 million for the nine months ended September&#160;30, 2022, compared to other net expense of $9.5 million for the nine months ended September&#160;30, 2021. The current-period reduction in other net expense for the current-year third quarter, and increase in other current net income for the current-year nine months, resulted primarily from the remeasurement of the contingent earnout liability associated with the August 2021 merger with Alpha Healthcare Acquisition Corp. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $25.3 million for the third quarter of 2022, compared to $31.6 million for the third quarter of 2021, and net loss was $8.2 million for the nine months ended September&#160;30, 2022, compared to $69.1 million for the nine months ended September&#160;30, 2021. The current-period decreases in net loss resulted from the reductions in other net expense and increase in other net income described above, partially offset by operating expense increases also described above.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Thursday, November 10, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-844-826-3033<br>International&#58; 1-412-317-5185<br>Conference ID&#58; 10171750</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit </font><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.Humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials&#59; the anticipated characteristics and performance of our HAVs&#59; our ability to successfully complete, preclinical and clinical trials for our HAVs&#59; the anticipated benefits of our HAVs relative to existing alternatives&#59; the benefits and risks related to our humanitarian efforts in the Ukraine&#59; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; our rights and obligations under our partnership with Fresenius Medical Care&#59; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology&#59; the timing or likelihood of regulatory filings and approvals&#59; timing, scope, and rate of reimbursement for our HAVs&#59; the outcome of our ongoing discussions with the FDA concerning the design of our ongoing V005 Phase II&#47;III clinical trial, including determination of trial size, and the scope of any approved indication for our HAVs&#59; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the impact of COVID-19 on Humacyte&#8217;s business, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those included under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2021, filed by Humacyte with the SEC and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LifeSci Advisors LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-617-435-6602</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Humacyte Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Elizabeth Miller</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LifeSci Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-704-299-6016</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">emiller&#64;lifescicomms.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id66ef82128f44905b9d61a27a37616fa_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Revenue</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,337&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,386&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,303&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,091&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,188&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,576&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,525&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,784&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,353&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,667&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23,494)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,543)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(63,788)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59,581)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(962)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,768)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,649&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,768)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income (net)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,252)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,106)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,787)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,020)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,543&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,481)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,281)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,563)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,245)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(69,062)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.72)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.69)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,031,980&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,950,856&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,014,009&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,728,471&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="id66ef82128f44905b9d61a27a37616fa_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,731&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,612&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,340&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,026&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,581&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226,219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,286&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,906&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,011&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, net of current portion</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,286&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,442&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107,547</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164,359</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,490&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422,818)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,573)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,672&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,174&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226,219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20221110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a2ee5820-b42e-4233-97a4-541eaa39e606,g:448f800f-0fd0-43fb-85cb-7b31a34c1e9b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20221110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20221110">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20221110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20221110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20221110_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20221110_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a2ee5820-b42e-4233-97a4-541eaa39e606,g:448f800f-0fd0-43fb-85cb-7b31a34c1e9b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20221110.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended" id="i21b5d04b98b44fec827770dbb380b868_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_05200ef4-4710-462f-b30d-4905e635d192" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_DocumentType_05200ef4-4710-462f-b30d-4905e635d192" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f8f15456-e547-4d0e-ad74-e5954fcdc044" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_DocumentPeriodEndDate_f8f15456-e547-4d0e-ad74-e5954fcdc044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_998e0c1e-07ae-405e-97ce-f79b76db580a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityRegistrantName_998e0c1e-07ae-405e-97ce-f79b76db580a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1cc8bbba-59e0-42a1-9309-68c0ac3ed3a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1cc8bbba-59e0-42a1-9309-68c0ac3ed3a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d18c5589-c715-4d7a-8da9-71b6900504d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityFileNumber_d18c5589-c715-4d7a-8da9-71b6900504d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a6590b9-7796-4d86-9c6a-797fef7629f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a6590b9-7796-4d86-9c6a-797fef7629f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e2d34297-6c95-44fc-83ad-272188547893" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressAddressLine1_e2d34297-6c95-44fc-83ad-272188547893" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2dbcef66-8ee2-419e-be7f-b5f35ef90d9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressCityOrTown_2dbcef66-8ee2-419e-be7f-b5f35ef90d9b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_70b66401-80a5-4274-a64d-ad099a66f75c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressStateOrProvince_70b66401-80a5-4274-a64d-ad099a66f75c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_95bb7cab-22d5-4600-a9d7-7bcaf689bb00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressPostalZipCode_95bb7cab-22d5-4600-a9d7-7bcaf689bb00" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_39d6375b-e1e5-470c-9c89-4ffdcdcdbfe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_CityAreaCode_39d6375b-e1e5-470c-9c89-4ffdcdcdbfe4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_59f0e01c-bd00-4594-997c-1a3d5424b120" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_LocalPhoneNumber_59f0e01c-bd00-4594-997c-1a3d5424b120" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8fe2951d-2b35-4be0-b1ec-17a3e4df0736" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_WrittenCommunications_8fe2951d-2b35-4be0-b1ec-17a3e4df0736" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_1413560a-85e4-438e-8b32-80e7b60ccb35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_SolicitingMaterial_1413560a-85e4-438e-8b32-80e7b60ccb35" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0c9338aa-dd09-4357-bf47-fb72bb19355f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_PreCommencementTenderOffer_0c9338aa-dd09-4357-bf47-fb72bb19355f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3a04c8ab-27bd-4e56-84dd-d5cc0aa43d28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3a04c8ab-27bd-4e56-84dd-d5cc0aa43d28" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a6256f8-df03-4176-9794-cc9bb6ddb90c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_Security12bTitle_4a6256f8-df03-4176-9794-cc9bb6ddb90c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bb70fca1-4f08-4909-88ea-28186ab5bbbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_TradingSymbol_bb70fca1-4f08-4909-88ea-28186ab5bbbd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_374d5af4-78c7-4d33-afa0-dd41e9e92c28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_SecurityExchangeName_374d5af4-78c7-4d33-afa0-dd41e9e92c28" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1411e87f-0a34-43f4-97d5-009f638252bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_1411e87f-0a34-43f4-97d5-009f638252bb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_89161330-705e-4dab-9c09-6a6f62af11ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityExTransitionPeriod_89161330-705e-4dab-9c09-6a6f62af11ce" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d8daeaee-4066-404a-8735-266a87d909e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityCentralIndexKey_d8daeaee-4066-404a-8735-266a87d909e6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fc097685-2bdc-4afc-a292-e54d259aa835" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_AmendmentFlag_fc097685-2bdc-4afc-a292-e54d259aa835" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1409224a-f690-4b4d-bb78-b3d5dd28196c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:to="loc_us-gaap_ClassOfStockDomain_1409224a-f690-4b4d-bb78-b3d5dd28196c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:to="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_662b09ca-b7a1-4efe-ae70-e534f6410bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:to="loc_us-gaap_CommonStockMember_662b09ca-b7a1-4efe-ae70-e534f6410bde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1d349268-9e23-47c9-a98b-59f5321a5263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:to="loc_us-gaap_WarrantMember_1d349268-9e23-47c9-a98b-59f5321a5263" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20221110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a2ee5820-b42e-4233-97a4-541eaa39e606,g:448f800f-0fd0-43fb-85cb-7b31a34c1e9b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_86dcb420-003d-4c18-a63e-0b32bb6639a0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6b230e0d-8dd3-4b2e-b7e0-7e3561eeccb8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bf22121e-d997-4fbe-8bda-7bc485507760_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_35d56bd8-44c4-4e35-b436-cce9436d1972_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_95098c19-1927-4ac8-a2a0-60db870255c9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5045d0ee-4668-4150-9ec2-8c57779705bc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5c683f2d-8ebc-4ce4-b381-16fb10482e75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_dcc0a7dc-2471-42a5-8495-cd1142115501_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_afe3d653-4ea0-4c50-8a02-a535feb0bbec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f51e7fc3-2555-49e8-80cd-fa3493ceec26_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_3edb9f1e-a1ff-4520-b347-3c641685ddab_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cc1a9340-126f-48d9-84d4-e34b1ccc41bf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6776ca5c-c839-4a6a-9f30-25e6b19e5ccb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_d46f8fc0-0c52-4f1a-b33b-74fec387c7b1_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ed07237e-fdd4-4392-8985-e52820edb50e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_51438c53-0b7f-43d7-9f9c-655680476bee_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4be03ea8-51f6-459b-81a3-276c604d396c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_59d1546e-8fa2-4e62-bd1c-883825c94a31_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_78943cfd-c518-437f-8fac-eb93fa4be0d0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_2aee71eb-947d-4885-8e8a-b7bc129ff188_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b8cb666c-f4ed-41ba-82ee-bdaa549f7689_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_faa601db-a298-45ef-a0f2-38dac902320f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_008f7a6c-1183-4562-8583-7bab4612517b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5fe0b29d-8c1c-4c59-8a51-f060ffc62eb0_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_69f5ab03-c5cb-44f0-95cc-8b95591b4378_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_87baa18f-fb4f-4198-af04-c27dd1d994b5_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f9afa8c4-10ce-49e5-b929-44158692408a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_812be35b-1b23-4f0a-9f08-5c85e9c57466_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d597d480-0695-446d-8788-8980f881f5dd_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20221110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a2ee5820-b42e-4233-97a4-541eaa39e606,g:448f800f-0fd0-43fb-85cb-7b31a34c1e9b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20221110.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ed05a189-0a66-4841-b495-6d6df1a1e682" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ed05a189-0a66-4841-b495-6d6df1a1e682" xlink:to="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1409224a-f690-4b4d-bb78-b3d5dd28196c" xlink:to="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_662b09ca-b7a1-4efe-ae70-e534f6410bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:to="loc_us-gaap_CommonStockMember_662b09ca-b7a1-4efe-ae70-e534f6410bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1d349268-9e23-47c9-a98b-59f5321a5263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_282e06d6-7e7b-4db2-82ab-b2b00e16fd4d" xlink:to="loc_us-gaap_WarrantMember_1d349268-9e23-47c9-a98b-59f5321a5263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e6d057a1-71e2-4d15-b478-ab09245f81c1" xlink:to="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_05200ef4-4710-462f-b30d-4905e635d192" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_DocumentType_05200ef4-4710-462f-b30d-4905e635d192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f8f15456-e547-4d0e-ad74-e5954fcdc044" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_DocumentPeriodEndDate_f8f15456-e547-4d0e-ad74-e5954fcdc044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_998e0c1e-07ae-405e-97ce-f79b76db580a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityRegistrantName_998e0c1e-07ae-405e-97ce-f79b76db580a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1cc8bbba-59e0-42a1-9309-68c0ac3ed3a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1cc8bbba-59e0-42a1-9309-68c0ac3ed3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d18c5589-c715-4d7a-8da9-71b6900504d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityFileNumber_d18c5589-c715-4d7a-8da9-71b6900504d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a6590b9-7796-4d86-9c6a-797fef7629f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a6590b9-7796-4d86-9c6a-797fef7629f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e2d34297-6c95-44fc-83ad-272188547893" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressAddressLine1_e2d34297-6c95-44fc-83ad-272188547893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2dbcef66-8ee2-419e-be7f-b5f35ef90d9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressCityOrTown_2dbcef66-8ee2-419e-be7f-b5f35ef90d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_70b66401-80a5-4274-a64d-ad099a66f75c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressStateOrProvince_70b66401-80a5-4274-a64d-ad099a66f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_95bb7cab-22d5-4600-a9d7-7bcaf689bb00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityAddressPostalZipCode_95bb7cab-22d5-4600-a9d7-7bcaf689bb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_39d6375b-e1e5-470c-9c89-4ffdcdcdbfe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_CityAreaCode_39d6375b-e1e5-470c-9c89-4ffdcdcdbfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_59f0e01c-bd00-4594-997c-1a3d5424b120" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_LocalPhoneNumber_59f0e01c-bd00-4594-997c-1a3d5424b120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8fe2951d-2b35-4be0-b1ec-17a3e4df0736" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_WrittenCommunications_8fe2951d-2b35-4be0-b1ec-17a3e4df0736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_1413560a-85e4-438e-8b32-80e7b60ccb35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_SolicitingMaterial_1413560a-85e4-438e-8b32-80e7b60ccb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0c9338aa-dd09-4357-bf47-fb72bb19355f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_PreCommencementTenderOffer_0c9338aa-dd09-4357-bf47-fb72bb19355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3a04c8ab-27bd-4e56-84dd-d5cc0aa43d28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3a04c8ab-27bd-4e56-84dd-d5cc0aa43d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a6256f8-df03-4176-9794-cc9bb6ddb90c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_Security12bTitle_4a6256f8-df03-4176-9794-cc9bb6ddb90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bb70fca1-4f08-4909-88ea-28186ab5bbbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_TradingSymbol_bb70fca1-4f08-4909-88ea-28186ab5bbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_374d5af4-78c7-4d33-afa0-dd41e9e92c28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_SecurityExchangeName_374d5af4-78c7-4d33-afa0-dd41e9e92c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1411e87f-0a34-43f4-97d5-009f638252bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_1411e87f-0a34-43f4-97d5-009f638252bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_89161330-705e-4dab-9c09-6a6f62af11ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityExTransitionPeriod_89161330-705e-4dab-9c09-6a6f62af11ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d8daeaee-4066-404a-8735-266a87d909e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_EntityCentralIndexKey_d8daeaee-4066-404a-8735-266a87d909e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fc097685-2bdc-4afc-a292-e54d259aa835" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_6ba52fde-5df6-43ba-99e2-7be8a34f85e0" xlink:to="loc_dei_AmendmentFlag_fc097685-2bdc-4afc-a292-e54d259aa835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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MRELR"2*Q9G*LK#!7,QK65WIJ7<UI7E-:O59%!;DFNF)L\ ^ 2BG!/;2D4;C
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MH6G.!3UMTVF.ZG( "B*RO>25^/333\M/T"('J7#050TNO/#"\A-?\4K'[3
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M9&O@_JA1J$[0:UL,3)M <SJCORV$+@\B?%@58B1CE(N7N2K8Q4IOI:""AHG
M_.(2BL8#[F6FQQJ;VK3,G-"2HYEK\"<@$M32BHX@(A5@U&C=EWLL\^V/Z[_R
M28.M4[9)PWIOE 2WBP!SYLS3G_[PYW#$/_D=#P=_?NJIIT(X>BSWJ@'X07B&
M,XB)M'SVV6?+7\\%:# DIG< F(VT $\;!D8B0.CXU6#.,#0P4M#S<Z C(86X
MGBS.P""O,,"<O%V%A$8*PS"\G82=>+AC\KX*^C2W"@)>+AB-H9?TZ02L=,1?
MGP H#YV#E0HZ,HS)*@MAG)D=/%V6JZ EY?-[O[VN'J8J<#]HP>MOE,M5I^H
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MXYJ:7K^6QM2KK0DV:Y]SPS4V _]8N0MFFO0P'2W13F76.<I,NH3S#>4-\H\
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M&=\KGYR.N\7#.7@<1T]O1\#S<_2TD@$W_/U5=^S; YY>2!MZX6;HRW^^/ =
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MZ7Q;8V#:C7+[/ #:LY%#_3'9X(F;K,AL#1*OU=,(4<.5,ZYC',(SX8B#61'
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MR;+'K6 %$#::$%<4(H&>?O G4@))@+7]F%/T[!AS_V6&!E 6^OHDW*?[[!2
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M:&:"5SU$,CH[5^6/6_1;#5:B$?F6^P0LAU\X1(_$"GW&(C(KBTII&,)&SSZ
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M^27,GS\_?'3\P@LO# /1\.'#RP< @#+$A:D+G3CP[&&P5Q4'P8@=0.-E $)
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M60&,YLK^"NF0GO<[GD$T>]J(=L8?'L&$OW$'&7S^YW_^)_ L_,JFK;\ ]?=
M. ?L"!D@8P4IL>'J/A -K A1*0B82 AGQTIARAV-&8)V;=,A0],E#/DM#C>8
MY1L6F:0/>2'%T5#YOGR^,0R=E'4;/K+(13QLP#$:;<FQ9]P0[*9Y8Q9;."Z1
M+LA1:<X&E1B6YB8^DY(;?2J%6]RX>3]<CT>>%,^ SW7/F#M7U]]RJW8U)OQ?
M.O"N?PT-2(>"21@9&2VQQY'1T]%'4Y#1U#>:$* T/@V.ML54>VL:, *8S@%C
MPA!T##1KIM" =S!'(-GNP(D#-MLX ^M,]M___=]AXXGUOV1AZL 2!--K!##E
M@&DYS8%VZ&N&Y.-E1[M":',B "&(0(*)86Z$&VGY]-[+&N^0"%EF&P@$CT?>
M+&>@C3L@@%VC\WHBS%G*(%\Z%!T(@<*Z+\L!<6$?SQ.@W)R39I.*>I(O[45Y
MH8'G0=OXE-[=6)8B7]J;^I(O/(/VQ.!&V@!QD]O,<5NPO>'B0'CRBY>5,CC-
M$"@L):'MTZ[0VX46LP"$&$LY7E\?]'86O#Q>%DP7P&BCO_G-;P)?0D,$\,XN
M0?B:/#STO__[OZ$MJ1>S,P953J:@ #";9.;CR+,CS_0U[!S]8T\FOGFWLU!)
M RZW5'*L !XA-S(693>A\ :,FL$C>2@CKOW%P\:;RT.#\32YP0QY:^T;EC@J
M/")DHXQWV,--_N&*29L6<MXLWU(!"TR(&I8D3C]P%66N"?0M907**<O7EE+#
MDNCSV]Q]&C+AK%HXKV;Q@]J.<ZGFF "^X:8;]6<3O+_Y[?_HOXTI$ "LB[&I
MP_26*2N(MH4)D[H;=D?",G5C)YQ3 ^SNPN@P&0(X60.F<P P.NXP 1HP@M*%
M LL!\6ETO%-CNMV?'2@'4TDVI"@#C+G++KN$HVT(4SJ9@Z<-($QY!9,.20=Q
M 8P&'!? E /T?.D\I,L96)91V'1DPPN:>;DPO?P.:*F\,LI Q: #HDTC"%EK
M=2 > A@D3];;6;^$/G0\R@K-H!\=COLN$.X@@IRT.&DR;MRX8&<MGA<"T)01
MO- :NA,?040<\@0H+WDZG3!95X1'J"OQ?OO;WX:!EF46!K[D*;S'Q\W=>79Z
MN#_H0!LA7!B<*3,T1BC$P\3CN7O\F?3C@I0CDM29,L,3"%\$(%-UWM[T-,@[
MGL[. /&\;OZ, &8/@9,N\"-M1ONA?+ 6NS, K5E#9D"A3K0% MB/7*+ ,!C[
M?@WH^SK^C(( XL8 "YV=;CM;?V"7(&P<0T()Q(XU 5AI(E@.-%$5S! ,SV"Q
M$$&#1(^UJ7Q UVV-D0R-Y!883$0,<>V?J &M00TYKQ@^V!G*9AX)#,=6+"#G
M=PLLKWQ#S'#?:%@^L&F=88$)U?PRT,*87Y[YY1MR-VF!,1VG.0I-RH?SP8GB
M1^4@7W,TX/-#<^:8 +[^1OWICW\.# '6K5<W:#(["ZQQTCE9 T4P@*QO(BP0
M. [>*0 T4C;^$-J4 <$'LEF$,$\>D6$*UPCC0,=A&LPF"NN2,"(# &DAY)CN
M^^86:20S%QT= 8Q0^J__^J\0#Z'"FEC\A1#*3N=V 0)0'@8MIO=L*B(PG($I
M9U6,S,##4H!/Y>E T I!GJP!NT $$.QT.F8,"$_*Z1H[\5G&0 /'GS5]T$\M
M@.Z&YDI\D Y,&5BS1R"0/W5R2*874U]>5V6]&^%+QT>@(931PO&#GLDOTCA-
M0+?'@>4A!@NFP9R9AB= [&QL,G@X+:J*[^!YQ(%I/@(8'D,(,^ A %F:8GW>
M@71!A^KRV!H0AW+&X\+G;(PQ0%,&9@^T/>>V=_84!(,42R>T 3Q+O6A7!G;.
M>2?WD1T!:)!<AQV!7<*.$\BMX['3#Y:B80A3#CPZE@,/M(,+2DO#R!K$;:']
M\ME.;*:6)A#-"N8@K,7Q!$-\1P0MHXMA2(_-P,2&H G4J/$M%TNBV,P@;"V/
M7/L%\PQYYF;^0O,+7\DU(G'TK,2$;OA@:)$QMU63,[]!\"=*561EXFH]@'Q@
MYNNONTY__/T?*@1PW;KA;2\7>! _&9,A[L8:(9?)T&E@")C,A4JR  [E3G0F
MA!>;>FP>($P01@@4! *=G#01;FA?,+(?TD>K0+-!8# UAO$0,@@4XI,. A7!
MRG* :[* E\&!Z3<='0:&%@@5!/!77WU5:=F"^GI<-UU(\LQ @)UPV%VC2@:T
M>Y8@$%SDQ6!%?7TIP,'CDH>_:8@V3QD1F@A7M"K6O*$5RT0L#;$DQ-( ;BS'
M@#SCQ_(2[@Q4;)(BB"@#0@GZL6D:/XD1+S]U!-"8V'QC;=5G#;0=94*3)WW.
M-".,N8."61/+0VA;KGDQ4/G A8 E7Y:QH(/3!#ZBC,G:.73UL@"4L2HZNUM<
M (.4%<&%!AQ7.D@3K"JM'85X&@PN"& $/OE3-Q0#UM1W5@#3WQ#@\#II0BL4
M#S:#&<3@,82TSUBA-1B?O28CIV6(1]H,H$[O'85=(H'H&!/ 020E .OV8H4E
M8=+XI!?/@\+B[N$,$M%H#"X#B80O8CR._,4%G:5B/[Q)8Z$M]6@U.=R$#\(@
M:-&674#+$EX,'Q'%;O&CL!8F9(\]$OQ 26F^9LR<K*NNODR_^_UORIF2Y0($
MF8^<7AYG2F=,=\., XW-D2AVE$F/$1D!F"R 76!Y?-)"N'(@'J& $(2I$."^
MOLD:+IM>:(VL;Z%I(3!YH8%.ZSO[GB]"F,[%9AY363\365W9T=C0DF%@IP=K
MABQ!Q#4YXB4C=7%TMSBMJ@+6Q+G_ H%%9P2I)W5C.<3!XR.P$&9H4&BM=#8&
M+([K43\T:A ZDS;H;MCI6'&DD[&4P7$U!+AK4-0;#9FU;09ISY_ZQ.E&7:$I
M2QW<Y8%P1_ RH##PT6ZT(>W/C(@!@/HBL+WM.&6"H/8C=-# VX\Z4@[:@"4E
MRHQ63K[;@JIHSN#%0.QM2_G(@\&,O0&/$S>K2F=' 'H!I(.R@*8-'WL9H-7?
MLP;,$@0GB* S-(.7J!-*#_E <XZ],1C[@(R9/"CCYF$9H!'@:-:<)6:PW!DH
M?Q'#T<@0PP3$G0+:3PRCOX2780 L)!=HZS[NX,]@'#RMZ*]RN.2PE<&+4PDJ
M1>6'O*WS)\Q@-RW9OW]543[0AHNB0M-PIEKC7V?:S]^LP_PN,#]"# W8IY\P
M#@SOC 3$F3*926$(EB!H?)\6TXG0;.("."ZLW 30JIB"LHQ 9V5#$ T/C0CF
M@FE=LW9A@4E>3.?0Q-@$A)G85$#S\K.P+D#B&"^[+T' O*1/?JP!5[4$D1P_
MG@[@^6'&P\3#(1010FPXTA$9,%@V0$N+"V  NC"EA":^WH?P9;D@KJGN#""8
M$.*<!/!=<_)@">BYYYZKM!$*>MO%@9D% I)SKBP;T8$YTXPV3?UH']H)],&&
M=G2A#Y^P>P__T>8,M!RO@O8L*_G@"233-DY3P/W!.#!38BG,9U<(*LK&AB*:
M*1HU$*];<MK;"\EEX!DZ<@X=98'Z0Q,&)P3=SIZ"\"4(VLW[ %H]"$]13V82
MU-F%,R;NR<CL!],'!@8^VC,^:]P1J/84!,BSNU?8K3'ME[_*^JD)B42XT!SQ
MA*K#&) JZ4:8\$P.7PD]?"+T+_P36 Y> [36"BQ?VC!_S]VAJ+!4LV;.U]UW
MWJ^&]9M8@[$3_]>P<84V0(=W2&9V1W>/ P*8VYF8!J/-H=70$=FIC;^(X<SI
M"-/[U)UGEA?0B-FMYTT?ILRD18=U[2&."$R6/3A#RT804RG2<&'AZ8+)]7!
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I7^%7^#?!KP+X5_@5?H5?X=\"TO\'GVM_Z3P1[XL     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139942696542240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>huma-20221110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20221110.xsd" xlink:type="simple"/>
    <context id="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="ia299eba8191d4c46a191713c02621e07_D20221110-20221110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl80L2ZyYWc6YmUxMmNlMWE1OTQ5NGM4OGI3ZTI5NjUwZmQwMDMwMjYvdGFibGU6MTg3YTJhMWJkNDZlNGY5YWEwMzBhNzQ2MTE1ZmViNWMvdGFibGVyYW5nZToxODdhMmExYmQ0NmU0ZjlhYTAzMGE3NDYxMTVmZWI1Y18xLTEtMS0xLTU3MTMz_11fd74d6-8bf8-435c-9b51-3f33c89fb2fc">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl80L2ZyYWc6YmUxMmNlMWE1OTQ5NGM4OGI3ZTI5NjUwZmQwMDMwMjYvdGFibGU6MTg3YTJhMWJkNDZlNGY5YWEwMzBhNzQ2MTE1ZmViNWMvdGFibGVyYW5nZToxODdhMmExYmQ0NmU0ZjlhYTAzMGE3NDYxMTVmZWI1Y18yLTEtMS0xLTU3MTMz_c55f599c-415c-4ea6-bbfc-447c503aaf6e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIw_5a0b0620-2494-49da-a2b6-d491135a1970">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIx_d59ca478-55dd-42af-a6c7-65a4b3753cd2">2022-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIy_901b3c41-4e53-4f5a-9c20-e1741e6890e4">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjIz_86603769-ed10-4824-b735-973509fb2049">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6NmQ1ZDIxNjZjNWU4NDZhM2JlM2I1YmYwODFhY2EyOTgvdGFibGVyYW5nZTo2ZDVkMjE2NmM1ZTg0NmEzYmUzYjViZjA4MWFjYTI5OF8wLTAtMS0xLTU3MTMz_d2f1ac13-e101-46be-ad86-5f273b224145">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6NmQ1ZDIxNjZjNWU4NDZhM2JlM2I1YmYwODFhY2EyOTgvdGFibGVyYW5nZTo2ZDVkMjE2NmM1ZTg0NmEzYmUzYjViZjA4MWFjYTI5OF8wLTEtMS0xLTU3MTMz_6f244117-23ba-41e4-a780-be38eda2b3ea">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6NmQ1ZDIxNjZjNWU4NDZhM2JlM2I1YmYwODFhY2EyOTgvdGFibGVyYW5nZTo2ZDVkMjE2NmM1ZTg0NmEzYmUzYjViZjA4MWFjYTI5OF8wLTItMS0xLTU3MTMz_5359243e-c489-4515-9571-813ede86f47c">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18wLTAtMS0xLTU3MTMz_c8b6103d-f234-4a12-87c5-03699a051139">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18xLTAtMS0xLTU3MTMz_9fa4c9af-b7e1-43a1-a3ac-6729b1204b1e">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18xLTEtMS0xLTU3MTMz_671711f5-6183-4328-a523-04287474643f">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6MTJlOWYxOWZkMzE1NDZiMzgxNDQ4YzVkZTFmMjA4YzcvdGFibGVyYW5nZToxMmU5ZjE5ZmQzMTU0NmIzODE0NDhjNWRlMWYyMDhjN18xLTItMS0xLTU3MTMz_92e7336b-d96d-436a-9f2d-196db9eb91c4">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8zMjU_c4c47d68-b877-43b9-b71f-abf4a6e173b8">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjI0_4954b877-3626-43ec-b2b8-43b5ae2a86a0">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8wLTAtMS0xLTU3MTMz_d23be0fb-8bc5-458a-a693-69796eb92568">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8xLTAtMS0xLTU3MTMz_92ed797e-1e64-4b17-8c74-b9f2701e69fe">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8yLTAtMS0xLTU3MTMz_819fd7e2-980a-4b0f-8ed5-d403325f413a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6OWNhMDNmZTY5MGNhNDM5YjhmYjQ3ODNiMWViMWVjZmQvdGFibGVyYW5nZTo5Y2EwM2ZlNjkwY2E0MzliOGZiNDc4M2IxZWIxZWNmZF8zLTAtMS0xLTU3MTMz_5acf124e-feff-4419-97d2-e2455f53d554">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8xLTAtMS0xLTU3MTMz_4240e115-f5b0-453a-af89-86980ee29ec4">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8xLTItMS0xLTU3MTMz_8f000705-e8b1-46d5-81f9-9db05297a6a4">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7a63aa7c3d76410e81e1e9e395502a12_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8xLTQtMS0xLTU3MTMz_ae8aff5e-0913-475b-b720-29dcc694ac85">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia299eba8191d4c46a191713c02621e07_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8yLTAtMS0xLTU3MTMz_37f03e42-0486-423a-9019-011f8023abe2">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia299eba8191d4c46a191713c02621e07_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8yLTItMS0xLTU3MTMz_471791b0-7852-46f5-bced-a7f0f7a5aa96">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia299eba8191d4c46a191713c02621e07_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGFibGU6ZmRjZjMxYjQ2NDAxNGRhMWI3NzNmYzczZjAyNWI1NWQvdGFibGVyYW5nZTpmZGNmMzFiNDY0MDE0ZGExYjc3M2ZjNzNmMDI1YjU1ZF8yLTQtMS0xLTU3MTMz_82c48db2-d72f-4c8e-bee3-0b931229a7c1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjE4_1da69b19-f2a8-4ea7-99e4-0468f0a59c81">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110"
      id="id3VybDovL2RvY3MudjEvZG9jOmE4MDU3YzM0OWIxYjQxYTA5ZGMzOWI4OGU1OGZlN2JiL3NlYzphODA1N2MzNDliMWI0MWEwOWRjMzliODhlNThmZTdiYl8xL2ZyYWc6MDhiOTM2ZTRiODlkNDU2MThmMzc2ZGI2MzVkOTZiMTIvdGV4dHJlZ2lvbjowOGI5MzZlNGI4OWQ0NTYxOGYzNzZkYjYzNWQ5NmIxMl8xMjE5_fb902e8c-4e89-4f9b-a28d-315e5875cca2">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( )0X:E49117U-P$  "<"   /
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( )0X:E5ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "4.&I5)!Z;HJT   #X 0
M&@              @ & $@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "4.&I599!YDAD!  #/ P  $P              @ %E$P
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  "O%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20221110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="huma-20221110.htm">huma-20221110.htm</File>
    <File>huma-20221110.xsd</File>
    <File>huma-20221110_def.xml</File>
    <File>huma-20221110_lab.xml</File>
    <File>huma-20221110_pre.xml</File>
    <File>huma-20221110xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "huma-20221110.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "huma-20221110_def.xml"
     ]
    },
    "inline": {
     "local": [
      "huma-20221110.htm"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20221110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20221110_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "huma-20221110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20221110",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20221110.htm",
      "contextRef": "i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.humacyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20221110.htm",
      "contextRef": "i5561169e47eb4e4c91a3902c2e8bb13c_D20221110-20221110",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001818382-22-000179-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-22-000179-xbrl.zip
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M^@#P&[FS-U 8<5H#(^:  X4)P5PH+Y?=@NG>4W56,GN?=5)90-1:O&E4!4H
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M()Q4_].".4Z0Q4;H+.K1_G_V$[!\P:.) R^OF 135B4 7_8V*@"&9KBQ/!M
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M%?'!8W^"A$>9(*XL4,YQ[VV4C?)9^;R,ZKU!&$U8G$WSHJ19._#-'2#Q;3E
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MJM.)[&)QS_ZP&=_G=7><_UC.;R3)D,4[_G\._I^N\+]"'8^(,L,>\SPLR\3
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MS=5AR75EX,2*LW.^4V7%NJ>]"BIJ0X/74:S#;RJ?V/A[U^7/M_>7.4N+I H
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M(G51)R^(.E$IU!B*H-S*GUP*G];OQ(7Y].K9ZIMD\7_0OGKV?U!+ P04
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M!;MG;A@*NU(575_)R1!X,7^D)/;K\ZMGMU]T+]VC\*^>_0]02P,$%     @
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M@. D0BEP7F&OP0T#)@O,-["G2"6@>$QD0<9#<'#45"5\K)#G8,]C'E,$0@&
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M/$*Q+WRR-*D<-;#!M _@"6 ]%+R^,D@ITDIAK?;);'B\'Z(W=6.+I3#NA7I
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MI@SR%"98^(B@H97G_ B_@]J^P2P!D(H+W [2@;+(Z(+@'_,V#\7[IU;5TCK
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MRM-TB-48" \'A, 05JH'6(63$<.BAC 94<SVU ?'U<@<3/"7E8J/Q\V?,0V
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M9X?4*U J%:S*T5,#O4JWV:QTZ^U*H]9H8+IVIFO"7M3TZI6&UZFTO&X++RI
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MJ!( =:0_0OP8[J )Z(B76"=5 C&@N$RA!Z+($$ VR('(2#'Y)D+WJYB6[97
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MTM-D"D<:W]\W/U R70ZCUV U-'O--_N5Y=Z!!_+,L%IS6\U&B=7GA=5V ^S
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M+TELP)8"F>+)&_M:3U<N\<F6^ Q]S^6>?^9[9B?6N$Z?*>'K>50"C[<*MG-
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M,C R,C$Q,3 N:'1M4$L! A0#%     @ E#AJ514,_EJ2 @  ^P@  !$
M         ( !KQ8  &AU;6$M,C R,C$Q,3 N>'-D4$L! A0#%     @ E#AJ
M5=!K\>ZN"   ,CX  !4              ( !<!D  &AU;6$M,C R,C$Q,3!?
M9&5F+GAM;%!+ 0(4 Q0    ( )0X:E76V^= 1 T  %%X   5
M  "  5$B  !H=6UA+3(P,C(Q,3$P7VQA8BYX;6Q02P$"% ,4    " "4.&I5
MRK_-9CL(  #80   %0              @ '(+P  :'5M82TR,#(R,3$Q,%]P
M<F4N>&UL4$L! A0#%     @ E#AJ54&)#.W1*0  .XP! !@
M ( !-C@  &AU;6$M,C R,C$Q,3!X97AX.3DQ+FAT;5!+!08     !@ & (T!
(   ]8@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
